Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Trastuzumab resistance: all roads lead to SRC

Nature Medicine volume 17, pages 416–418 (2011)Cite this article

Subjects

A new study shows how SRC, a nonmembrane tyrosine kinase, is a common signaling node in trastuzumab resistance caused by different mechanisms in HER2-positive breast cancers (pages 461–469). A SRC inhibitor restored trastuzumab sensitivity in vitro and in mouse tumor models, suggesting a new way to tackle drug resistance in breast tumors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Activation of SRC and development of trastuzumab resistance.

Marina Corral

References

  1. Slamon, D.J. et al. Science 235, 177–182 (1987).

    Article  CAS  Google Scholar 

  2. Yarden, Y. & Sliwkowski, M.X. Nat. Rev. Mol. Cell Biol. 2, 127–137 (2001).

    Article  CAS  Google Scholar 

  3. Baselga, J. et al. J. Clin. Oncol. 14, 737–744 (1996).

    Article  CAS  Google Scholar 

  4. Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  5. Ghosh, R. et al. Cancer Res. 71, 1871–1882 (2011).

    Article  CAS  Google Scholar 

  6. Hudis, C.A. N. Engl. J. Med. 357, 39–51 (2007).

    Article  CAS  Google Scholar 

  7. Garrett, J.T. & Arteaga, C.L. Cancer Biol. Ther. 11, 15045 (2011).

    Article  Google Scholar 

  8. Zhang, S. et al. Nat. Med. 17, 461–469 (2011).

    Article  Google Scholar 

  9. Blackwell, K.L. et al. J. Clin. Oncol. 28, 1124–1130 (2010).

    Article  CAS  Google Scholar 

  10. Burstein, H.J. et al. J. Clin. Oncol. 28, 1301–1307 (2010).

    Article  CAS  Google Scholar 

  11. Agus, D.B. et al. Cancer Cell 2, 127–137 (2002).

    Article  CAS  Google Scholar 

  12. Nagata, Y. Cancer Cell 6, 117–127 (2004).

    Article  CAS  Google Scholar 

  13. Andre, F. et al. J. Clin. Oncol. 28, 5110–5115 (2010).

    Article  CAS  Google Scholar 

  14. Lu, Y. et al. J. Biol. Chem. 278, 40057–40066 (2003).

    Article  CAS  Google Scholar 

  15. Mayer, E.L. & Krop, I.E. Clin. Cancer Res. 16, 3526–3532 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Senthil K. Muthuswamy is at the Ontario Cancer Institute, Campbell Family Breast Cancer Research Institute, University of Toronto, Toronto, Ontario, Canada, and at Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.,

    Senthil K Muthuswamy

Authors
  1. Senthil K Muthuswamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Senthil K Muthuswamy.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muthuswamy, S. Trastuzumab resistance: all roads lead to SRC. Nat Med 17, 416–418 (2011). https://doi.org/10.1038/nm0411-416

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0411-416

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer